Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327
ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up
to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.